ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
US Tech 100
21,198.40
1.36%
Dow Jones
43,297.03
0.91%
Brent Oil
73.285
0.80%
Bitcoin
98,674.10
4.21%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) News

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
16.44
-0.71
( -4.14% )
Updated: 13:28:09
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

RIGL News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
September 19 2024
RIGL (-4.14%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 04 2024
RIGL (-4.14%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 04 2024
RIGL (-4.14%)

Form 8-K - Current report
Edgar (US Regulatory)
September 03 2024
RIGL (-4.14%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
August 12 2024
RIGL (-4.14%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
August 06 2024
RIGL (-4.14%)

Form 8-K - Current report
Edgar (US Regulatory)
August 06 2024
RIGL (-4.14%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
August 02 2024
RIGL (-4.14%)

RIGL Discussion

View Posts
dcaf7 dcaf7 8 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 8 months ago
RIGL under $2
👍️0
Monksdream Monksdream 9 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 9 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 9 months ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 10 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 year ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 1 year ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 year ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 year ago
Better be good.
👍️0
bme bme 1 year ago
Ugly.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
base
👍️0
bme bme 2 years ago
What a shoot! Amazing.
👍️0
bme bme 2 years ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 2 years ago
nice fins
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
easy
👍️0
bme bme 2 years ago
Nice spike AH today.
👍️0
bme bme 2 years ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 2 years ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
quite the dip
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
bme bme 2 years ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 years ago
beauty
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Expect Q4 filing this week?
👍️0
bme bme 2 years ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 years ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

NASDAQ
RIGL
Rigel Pharmaceuticals
NASDAQ
FBUDX
Agf Global Sustainable G...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads